Mission Statement
To Cure A Rose is one of only a few nonprofits focused first and foremost on drug development for rare genetic diseases. We understand the systemic and financial obstacles that block progress in precision medicine and have created pathways for families who seek answers now. The TCAR process offers rapid diagnosis, research and therapeutic drug development for families in need.
Financial Overview — FY 2023
$492K
Total Revenue
$393K
Total Expenses
$203K
Net Assets
4
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
91.4%
Fundraising Efficiency
0.0%
Operating Reserve
6.21x
Liability-to-Asset
3.1%
Revenue Diversification
87.7%
Impact
1 program| Outcome / Program | People Served | Cost / Service | # Completed | Duration |
|---|---|---|---|---|
| mitigation of symptoms to cured | 1,000 | $65,000.00 | — | Lifetime |
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2023 | $492K | $393K | $203K | 91.4% | 4 |
| 2022 | $323K | $348K | N/A | — | 3 |
| 2021 | $430K | $85K | N/A | — | 0 |
Donor Reviews
No reviews yet
Be the first to share your experience with this organization.